What is the appropriate assessment and management plan for a 30‑ to 40‑year‑old woman with uncontrolled type 2 diabetes mellitus presenting with recurrent hyperglycemia, hypoglycemia‑related loss of consciousness, autonomic and peripheral neuropathy, orthostatic hypotension, possible lower‑respiratory infection, and currently on premixed insulin 70/30, sitagliptin, and atorvastatin?

Assessment and Plan for Uncontrolled Type 2 Diabetes with Loss of Consciousness

Primary Assessment

This patient requires immediate insulin regimen optimization and evaluation for treatment-induced neuropathy of diabetes (TIND), given the constellation of autonomic dysfunction, orthostatic hypotension, and loss of consciousness following rapid glycemic fluctuations. 1

Key Clinical Problems Identified:

1. Uncontrolled Type 2 Diabetes with Severe Hyperglycemia

   • Initial presentation with glucose 600 mg/dL and recurrent hyperglycemic episodes despite insulin therapy 2
   • Current regimen of premixed insulin 70/30 is inadequate for achieving glycemic control 2
   • The pattern of recurrent hyperglycemia after insulin discontinuation suggests insulin dependence 2

2. Hypoglycemia-Related Loss of Consciousness

   • Loss of consciousness while walking indicates severe hypoglycemia (Level 3) requiring immediate regimen modification 2, 3
   • The American Diabetes Association mandates that any episode of severe hypoglycemia requiring assistance triggers immediate treatment regimen re-evaluation 2, 4
   • Raise glycemic targets immediately to A1C 8.0% (64 mmol/mol) for at least several weeks to strictly avoid further hypoglycemia and partially reverse hypoglycemia unawareness 2, 4

3. Treatment-Induced Neuropathy of Diabetes (TIND)

   • Rapid HbA1c reduction (likely from 10%+ to lower levels) over recent months has precipitated acute autonomic and peripheral neuropathy 1
   • Clinical features include: orthostatic hypotension (BP 90/60 mmHg), circumoral numbness, muscle rigidity, bradykinesia, decreased sensation on left sole, and syncope 1, 5
   • This is a recognized complication of overly aggressive glycemic correction that presents with small fiber nerve damage 1

4. Diabetic Autonomic Neuropathy (DAN)

   • Orthostatic hypotension, loss of consciousness, and decreased peripheral sensation indicate established cardiovascular and peripheral autonomic neuropathy 5, 6, 7
   • Autonomic dysfunction increases risk of hypoglycemia unawareness, creating a dangerous cycle 6

5. Possible Respiratory Infection

   • Recent fever, productive cough with white sputum, and occupational exposure warrant evaluation 2

---

Immediate Management Plan

1. Insulin Regimen Restructuring (Priority #1)

Discontinue premixed insulin 70/30 immediately and transition to basal-bolus regimen with conservative dosing to prevent recurrent hypoglycemia 2:

• Basal insulin: Start long-acting insulin analog (glargine U-100, detemir, or degludec) at 0.2 units/kg/day given once daily 2

  • For this 58 kg patient: approximately 12 units daily 2
  • Administer at bedtime to minimize hypoglycemia risk 2

• Prandial insulin: Hold rapid-acting insulin initially given recent severe hypoglycemia 2

  • If premeal glucose >250 mg/dL, give 2 units of rapid-acting insulin 2
  • If premeal glucose >350 mg/dL, give 4 units of rapid-acting insulin 2
  • Stop sliding scale when not needed daily 2

• Target glucose range: 100-200 mg/dL (5.55-11.1 mmol/L) premeal, relaxed from standard targets due to hypoglycemia risk 2, 4

2. Discontinue Sitagliptin

Stop sitagliptin 50 mg twice daily immediately 2:

• DPP-4 inhibitors provide minimal additional benefit (0.7-1.0% A1C reduction) when insulin is optimized 2
• Simplifying the regimen reduces polypharmacy and medication errors 2
• Cost savings can be redirected toward glucose monitoring supplies 2

3. Continue Metformin with Monitoring

Restart or continue metformin 500 mg twice daily if renal function permits (eGFR ≥30 mL/min/1.73 m²) 2:

• Metformin is safe and effective as foundational therapy 2
• Check vitamin B12 levels now and annually, as metformin causes B12 deficiency that worsens neuropathy symptoms 2
• If B12 is low, supplement immediately as this may be contributing to peripheral neuropathy 2

4. Continue Atorvastatin

Maintain atorvastatin 40 mg daily for cardiovascular risk reduction 2

---

Diagnostic Workup

Immediate Laboratory Tests:

• Complete metabolic panel including creatinine, eGFR, electrolytes to assess renal function and rule out acute kidney injury (which increases hypoglycemia risk) 3
• HbA1c to establish current glycemic control baseline 2
• Vitamin B12 level given metformin use and worsening neuropathy 2
• Lipid panel (if not recently checked) 2
• Urinalysis and urine culture given history of UTI and current symptoms 2
• Chest X-ray to evaluate for pneumonia given productive cough and fever 2

Cardiovascular Autonomic Reflex Tests (CARTs):

Perform comprehensive cardiovascular autonomic function testing to confirm and quantify DAN/CAN 5, 6, 7:

• R-R variation during deep breathing 5
• Valsalva maneuver 5
• Postural blood pressure testing (lying to standing) 5
• These tests establish baseline autonomic function and guide therapeutic decisions 6, 7

---

Treatment of Autonomic Dysfunction

Orthostatic Hypotension Management:

Initiate pharmacotherapy for neurogenic orthostatic hypotension 6:

• Midodrine 2.5-10 mg three times daily (morning, midday, late afternoon—avoid evening dosing) 6
  • Start at lowest dose and titrate based on symptoms and standing blood pressure 6
• Fludrocortisone 0.1-0.2 mg daily if midodrine alone is insufficient 6
  • Monitor for fluid retention and hypokalemia 6

Non-Pharmacologic Measures:

• Increase fluid intake to 2-3 liters daily 5, 6
• Increase salt intake (unless contraindicated) 5, 6
• Wear compression stockings (waist-high, 30-40 mmHg) 5, 6
• Elevate head of bed 30 degrees at night 5, 6
• Rise slowly from lying/sitting positions 5, 6
• Avoid prolonged standing and hot environments 5, 6

---

Peripheral Neuropathy Management

Symptomatic Treatment:

Initiate pregabalin 75 mg twice daily for neuropathic pain (circumoral numbness, muscle rigidity, paresthesias) 1:

• Titrate up to 150 mg twice daily as needed for symptom control 1
• Alternative: gabapentin 300 mg three times daily, titrated to effect 1

Diabetic Foot Care:

• Formal diabetic foot examination revealed decreased sensation on left sole—this patient is at high risk for ulceration 5
• Prescribe therapeutic footwear and refer to podiatry 5
• Daily foot inspection by patient or caregiver 5
• Moisturize skin to prevent fissures (avoid between toes) 5

---

Hypoglycemia Prevention Protocol

Patient and Caregiver Education:

Prescribe glucagon emergency kit and train patient and household members on administration 2, 3:

• Glucagon is not limited to healthcare professionals and must be available at home 2
• For severe hypoglycemia with altered mental status, administer glucagon immediately 3

Hypoglycemia Treatment Algorithm:

For conscious patient with glucose ≤70 mg/dL 3:

1. Administer 15-20 grams of fast-acting carbohydrate (glucose tablets preferred) 3
2. Recheck glucose after 15 minutes 3
3. Repeat treatment if hypoglycemia persists 3
4. Once normalized, consume meal or snack to prevent recurrence 3

Glucose Monitoring:

Implement frequent self-monitoring of blood glucose (at least 4 times daily: fasting, before lunch, before dinner, bedtime) 2:

• Consider continuous glucose monitoring (CGM) if available, as it reduces hypoglycemia time by approximately 27 minutes daily in older adults 4
• CGM provides real-time alerts for impending hypoglycemia, critical for patients with hypoglycemia unawareness 4, 6

---

Glycemic Targets and Monitoring Schedule

Individualized A1C Target:

Target A1C 8.0% (64 mmol/mol) for this patient 2, 4:

• Rationale: Recent severe hypoglycemia, autonomic neuropathy, orthostatic hypotension, and occupational demands (parcel loader requiring physical activity) 2
• This relaxed target reduces hypoglycemia risk while maintaining adequate glycemic control 2, 4
• Maintain this target for at least 3-6 months to reverse hypoglycemia unawareness 2, 4

Insulin Dose Adjustment Protocol:

Every 2 weeks, adjust insulin based on premeal glucose patterns 2:

• Goal: 90-150 mg/dL (5.0-8.3 mmol/L) before meals 2
• If ≥50% of premeal values over 2 weeks are above goal, increase basal insulin by 2 units 2
• If >2 premeal values per week are <90 mg/dL, decrease basal insulin by 2-4 units 2

---

Respiratory Infection Evaluation

Evaluate for community-acquired pneumonia given fever, productive cough, and occupational exposure 2:

• Chest X-ray to rule out infiltrate 2
• If pneumonia confirmed, initiate appropriate antibiotic therapy 2
• During acute illness, patients are at higher risk for medication errors and hypoglycemia—consider temporary hospitalization if unable to manage diabetes safely at home 2

---

Follow-Up and Monitoring

Short-Term (1-2 Weeks):

• Telephone follow-up to assess for hypoglycemia, review glucose logs, and adjust insulin doses 2
• Ensure patient/caregiver can demonstrate proper insulin administration and hypoglycemia treatment 2
• Review symptoms of orthostatic hypotension and effectiveness of midodrine/fludrocortisone 6

Medium-Term (4-6 Weeks):

• Office visit to review glucose logs and adjust insulin regimen 2
• Assess neuropathic pain control and titrate pregabalin as needed 1
• Check standing and supine blood pressure to evaluate orthostatic hypotension treatment 6
• Review vitamin B12 results and initiate supplementation if deficient 2

Long-Term (3 Months):

• Repeat HbA1c to assess glycemic control 2
• Repeat cardiovascular autonomic reflex tests to monitor DAN progression 5, 7
• Annual screening for cognitive impairment using Mini-Cog or Montreal Cognitive Assessment, as cognitive decline and severe hypoglycemia have bidirectional relationship 4
• Annual vitamin B12 monitoring while on metformin 2

---

Critical Pitfalls to Avoid

1. Do not aggressively lower glucose targets after severe hypoglycemia—this is the most dangerous error and can lead to recurrent severe hypoglycemia and permanent neurologic injury 2, 4

2. Do not continue premixed insulin 70/30 in patients with hypoglycemia—this formulation provides inflexible dosing and increases hypoglycemia risk 2

3. Do not assume routine glucose monitoring prevents neuroglycopenic brain injury—fatal injury can occur within 2 hours of hypoglycemia onset 4

4. Do not overlook vitamin B12 deficiency in metformin-treated patients with worsening neuropathy—this is a reversible cause of neuropathy 2

5. Do not attribute all symptoms to diabetes alone—evaluate for acute illness (pneumonia, UTI) that can precipitate metabolic decompensation 2, 8

6. Do not delay glucagon prescription—every insulin-treated patient at risk for severe hypoglycemia must have glucagon available at home 2, 3

---

Prognosis and Patient Counseling

Explain to the patient that TIND symptoms typically improve over weeks to months with symptomatic treatment and avoidance of further rapid glycemic fluctuations 1:

• Gradual glycemic improvement is safer than rapid correction 1
• Autonomic symptoms (orthostatic hypotension, syncope) should improve with pharmacotherapy and non-pharmacologic measures 6
• Neuropathic pain typically responds to pregabalin or gabapentin 1

Emphasize the critical importance of hypoglycemia prevention 4:

• Severe hypoglycemia increases dementia risk and can cause permanent cognitive impairment 4
• Cognitive decline and hypoglycemia create a vicious cycle—each worsens the other 4
• Strict avoidance of hypoglycemia for several weeks can partially reverse hypoglycemia unawareness 2, 4

Address occupational safety concerns 2:

• Patient works as parcel loader/scanner requiring physical activity and alertness 2
• Risk of hypoglycemia-related injury (falls, accidents) is significant 2
• Consider temporary work restrictions until glycemic stability achieved and hypoglycemia risk minimized 2